Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Update : N.Y. Jury Delivers $25 Million Judgment Against Johnson & Johnson -- Bloomberg

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/21/2019 | 01:42pm EDT

(Adds company comment)

-- A New York jury said Johnson & Johnson (JNJ) must pay $25 million to a woman who claims she got cancer by using the company's products, Bloomberg reports Tuesday.

-- The woman alleged she got a rare type of cancer, linked to asbestos, from some of the company's products which contain talc, the report said.

-- The $25 million is for compensatory damages, and the jury will reconvene next week to consider a punitive penalty, the report said.

-- Johnson & Johnson has denied all allegations that its baby powder contained asbestos.

-- Johnson & Johnson said "This trial suffered significant legal and evidentiary errors," adding it had moved for a mistrial. The company also said "we believe these errors will warrant a reversal on appeal."

Full story: https://www.bloomberg.com/news/articles/2019-05-21/johnson-johnson-loses-25-million-new-york-talc-verdict?utm_source=google&utm_medium=bd&cmpId=google

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
06/14JOHNSON & JOHNSON : Janssen Says Guselkumab Psoriatic Arthritis Studies Meet End..
DJ
06/14JOHNSON & JOHNSON : New data from Janssen presented at the Annual European Congr..
AQ
06/12JOHNSON & JOHNSON : Judge orders Johnson & Johnson, Colgate to pay $10M in cance..
AQ
06/12COLGATE PALMOLIVE : J&J, Colgate-Palmolive Ordered to Pay Nearly $10 Million in ..
DJ
06/12MARKETS RIGHT NOW : Stocks fall for the 2nd day in a row
AQ
06/12JOHNSON & JOHNSON : Janssen Pharmaceutical - INVOKANA Significantly Reduced Majo..
AQ
06/12MARKETS RIGHT NOW : US stocks are mixed in early trading
AQ
06/12MEDCOLCANNA ORGANICS : Strengthens Board of Directors with Addition of Pharmaceu..
AQ
06/12GENMAB : J&J bags $150M option on Genmab's Darzalex successor
AQ
06/11JOHNSON & JOHNSON : Genmab, Janssen in Cancer-Drug Licensing Deal
DJ
More news
Financials ($)
Sales 2019 81 218 M
EBIT 2019 25 617 M
Net income 2019 19 737 M
Debt 2019 8 610 M
Yield 2019 2,71%
P/E ratio 2019 19,49
P/E ratio 2020 17,71
EV / Sales 2019 4,64x
EV / Sales 2020 4,25x
Capitalization 368 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 149 $
Spread / Average Target 7,4%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON8.55%348 981
PFIZER-2.04%233 072
ROCHE HOLDING LTD.13.11%227 848
NOVARTIS20.71%220 893
MERCK AND COMPANY9.02%206 641
ELI LILLY AND COMPANY-3.44%113 364